What question did this study set out to answer?

To review the pathophysiology, risk factors, and clinical evidence regarding pharmacological prophylaxis of atrial fibrillation in patients undergoing coronary artery bypass graft surgery.

October 1, 2012Cardiovascular & Hematological Agents in Medicinal Chemistry

Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis

Q: What is the clinical evidence from this study?

Study design: Review. Population: Postoperative atrial fibrillation in patients undergoing CABG. Intervention: Pharmacologic prophylaxis.

View Full Paper

Ask AI

Bookmark

Key result

Various pharmacologic agents, including antiarrhythmics, statins, and hydrocortisone, have been investigated and shown to decrease the incidence of postoperative atrial fibrillation after CABG.

Why the study?

Does pharmacologic prophylaxis prevent postoperative atrial fibrillation in patients undergoing surgical revascularization?

Population

Patients undergoing surgical revascularization (CABG)

Design

Review

Authors

CRCarlo RostagnoUniversity of Florence

Discussion

Member takes

Implication

Warrants vigilant POAF monitoring after CABG; leaves open targeted prevention to reduce late mortality.

Key Points

To review the pathophysiology, risk factors, and clinical evidence regarding pharmacological prophylaxis of atrial fibrillation in patients undergoing coronary artery bypass graft surgery.
Narrative review summarizing clinical trials and current evidence on pharmacological prevention of postoperative atrial fibrillation.
Evaluated interventions including traditional antiarrhythmic agents, ranolazine, polyunsaturated fatty acids, nonsteroidal anti-inflammatory drugs, corticosteroids, and statins.
Postoperative atrial fibrillation develops in 20% to 50% of surgical revascularization patients (with 40% experiencing recurrent episodes), peaking between postoperative days 2 and 3 and elevating late mortality risk.
Established antiarrhythmic agents (amiodarone, metoprolol, sotalol, propafenone, landiolol) effectively decrease arrhythmia incidence, while preliminary data support ranolazine pretreatment.
Anti-inflammatory regimens show mixed utility: hydrocortisone and statins significantly lower postoperative risk, while naproxen trials were terminated early due to nephrotoxicity.

Structured PICO

Does pharmacologic prophylaxis prevent postoperative atrial fibrillation in patients undergoing surgical revascularization?

Population

Patients undergoing surgical revascularization (CABG)

Intervention

Pharmacologic prophylaxis (including antiarrhythmic drugs, PUFA, ranolazine, hydrocortisone, and statins)

Outcome

Incidence of postoperative atrial fibrillation (POAF)

Various pharmacologic agents, including antiarrhythmics, statins, and hydrocortisone, are effective in reducing the incidence of postoperative atrial fibrillation following surgical revascularization.

Cite This Study

Carlo Rostagno (2012) conducted a review in Postoperative atrial fibrillation in patients undergoing CABG. Pharmacologic prophylaxis was evaluated. Various pharmacologic agents, including antiarrhythmics, statins, and hydrocortisone, have been investigated and shown to decrease the incidence of postoperative atrial fibrillation after CABG.

synapsesocial.com/papers/6a6cf4dbfebe604dd707a217 https://doi.org/10.2174/187152512803530306

Topics

Persistent AF management Atrial fibrillation Anticoagulation in AF AF ablation outcomes

View Full Paper

Ask AI

Bookmark

Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider